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Background: Electronic cigarettes (e-cigarettes or electronic nicotine delivery systems [ENDS]) are electrically
powered devices generally similar in appearance to a cigarette that deliver a propylene glycol and/or glycerol mist
to the airway of users when drawing on the mouthpiece. Nicotine and other substances such as flavourings may
be included in the fluid vaporised by the device. People report using e-cigarettes to help quit smoking and studies
of their effects on tobacco withdrawal and craving suggest good potential as smoking cessation aids. However, to
date there have been no adequately powered randomised trials investigating their cessation efficacy or safety. This
paper outlines the protocol for this study.
Methods/design: Design: Parallel group, 3-arm, randomised controlled trial. Participants: People aged ≥18 years
resident in Auckland, New Zealand (NZ) who want to quit smoking. Intervention: Stratified blocked randomisation to
allocate participants to either Elusion™ e-cigarettes with nicotine cartridges (16 mg) or with placebo cartridges (i.e.
no nicotine), or to nicotine patch (21 mg) alone. Participants randomised to the e-cigarette groups will be told to
use them ad libitum for one week before and 12 weeks after quit day, while participants randomised to patches
will be told to use them daily for the same period. All participants will be offered behavioural support to quit from
the NZ Quitline. Primary outcome: Biochemically verified (exhaled carbon monoxide) continuous abstinence at six
months after quit day. Sample size: 657 people (292 in both the nicotine e-cigarette and nicotine patch groups and
73 in the placebo e-cigarettes group) will provide 80% power at p = 0.05 to detect an absolute difference of 10% in
abstinence between the nicotine e-cigarette and nicotine patch groups, and 15% between the nicotine and
placebo e-cigarette groups.
Discussion: This trial will inform international debate and policy on the regulation and availability of e-cigarettes. If
shown to be efficacious and safe, these devices could help many smokers as an alternative smoking cessation aid
to standard nicotine products.
Trial registration: Australian NZ Clinical Trials Registry (ACTRN12610000866000).
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Most smokers want to quit and make attempts to do so
but the majority of these attempts fail largely because of
their dependence on nicotine and non-nicotine sensory
and behavioural cues that reinforce their smoking behav-
iour [1]. Psychological and pharmacological smoking
cessation treatments help smokers quit and are one
of the most cost-effective health interventions avail-
able [2]. Indeed, nicotine replacement therapy (NRT)
almost doubles quit rates irrespective of the level of
additional behavioural support [3]. Nevertheless, ab-
solute long-term quit rates with NRT are low: typic-
ally, fewer than 20% of people quitting with NRT
plus behavioural support are still abstinent at 12 -
months [3]. Even the most rapid-acting and highest
strength NRT products do not deliver nicotine in
doses or at the same speed as cigarettes [4]. With
the possible exception of the nicotine inhalator, nei-
ther do they replace the sensory and behavioural
cues associated with cigarette use. Indeed, many
smokers find available NRTs unhelpful, unpleasant or
difficult to use and want more product choice [5].
Electronic nicotine delivery systems (ENDS), more
commonly known as electronic cigarettes (hereafter
abbreviated to 'e-cigarettes' or 'e-cigs'), are so-called
because of their physical resemblance to a standard
tobacco cigarette and their electronic vapour-
generating mechanism. In 2004 a Beijing-based com-
pany, Ruyan Group (Holdings) Ltd, patented and
launched the first of these devices [6]. Many other
manufacturers have since made similar devices. All
contain a mouthpiece, a micro-electrical circuit, a
vaporiser, and a rechargeable lithium ion battery. The
solution in replaceable cartridges or used to fill a res-
ervoir in some models typically contains a solution of
humectants (e.g. propylene glycol and/or glycerol),
and nicotine and flavourings. When a user draws air
through the e-cigarette the micro-electrical circuit ac-
tivates an electric coil to heat and vaporise a small
amount of the nicotine solution, creating a visible
cloud of mist that may be inhaled by the user [7].
It has been hypothesised that e-cigarettes could be
more effective than NRT at helping people quit smoking
by delivering nicotine together with mimicking the phys-
ical, sensory and behavioural aspects of cigarette use
[1,8]. In international online surveys one of the key rea-
sons people report buying e-cigarettes is to help quit
smoking [9,10].
In 2008 we undertook the first study of the effect
of the e-cigarettes on desire to smoke and withdrawal
symptoms and found that they were as effective as
the NRT inhaler on reducing withdrawal but more
pleasant and acceptable to use [8]. Further research
has generally supported these early findings, and noneto date have found evidence of harm [6]. We also
found that the speed of nicotine delivery and serum
levels obtained was substantially less than tobacco
cigarettes. This has been corroborated with other
brands by other research groups [11,12].
A related question is the extent to which any
quitting assistance provided by e-cigarettes might be
attributable simply to the behavioural replacement
they provide, as suggested by a study of a nicotine-
free inhaler device by Capponeto et al. [13]. This is
relevant to countries such as New Zealand where
e-cigarettes are available for sale over the counter
but without cartridges containing nicotine.
E-cigarette sales are increasing rapidly: in the US
alone there are an estimated 2.5 million users with
sales of $300 million a year [14]. Internet search vol-
umes have surpassed search volumes for both NRT
and varenicline in the UK, US and Canada [15]. Des-
pite this evidence of consumer demand, there are
mixed views in the tobacco control community as to
what role, if any, e-cigarettes might play in helping
smokers to cease tobacco use. Strong concerns have
been expressed over their potential to be a gateway to
tobacco smoking, the safety of the inhaled vapours
and ability of the devices to deliver nicotine as
claimed [16-18].
Although a few studies have been conducted that
show promise for the potential of e-cigarettes as
cessation aids [19-21], none have been adequately
powered. As noted, a number of surveys of users
suggest potential in this area, but to date, no
randomised trials that evaluate the long- term efficacy
e-cigarettes on abstinence, in smokers motivated to
quit, have been completed. Nor has there been a
systematic evaluation of their safety. A well-designed
trial is urgently needed to inform policy develop-
ment on the regulation and availability of these and
the many other emerging nicotine cigarette substi-
tute products [22,23].
Aim
The primary aim of the trial is to assess the effect-
iveness, acceptability, patterns of use and safety of e-
cigarettes as a smoking cessation aid. The study will
determine the quit rates of smokers using nicotine
versus nicotine patch and versus placebo (non-nico-
tine) e-cigarettes at six months. The trial hypotheses
are:
 nicotine e-cigarettes are more effective than
nicotine patches on smoking abstinence at six
months;
 nicotine e-cigarettes are more effective than placebo
e-cigarettes on smoking abstinence at six months;
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placebo e-cigarettes at relieving withdrawal
symptoms and suppressing cravings to smoke;
 e-cigarettes are safe to use over a 13 week period;
 e-cigarettes are an acceptable treatment for smokers
trying to quit.
Methods/design
Design
A three-arm, parallel-group randomised controlled trial.
Study population
People from throughout Auckland, New Zealand, who
smoke tobacco cigarettes and are motivated to quit.
Inclusion and exclusion criteria
Participants will be eligible provided they are at least 18 -
years of age, have smoked at least 10 cigarettes a day for
the past year, want to stop smoking, are able to provide
verbal consent and have access to a telephone. Pregnant
and breastfeeding women will be excluded, as will be
people using other smoking cessation medications
(including other forms of NRT, bupropion, clonidine,
nortriptyline or varenicline) or who are clients of a
smoking cessation programme or enrolled in another
trial. People will be excluded if they report having had a
heart attack, stroke or severe angina in the previous two
weeks; poorly controlled asthma or other airways disease
from self-report; poorly controlled diabetes mellitus; se-
vere allergies; poorly controlled psychiatric disorders or
current chemical dependence other than that involving
nicotine.
Recruitment
People resident in the Auckland region will be informed
of the trial through short articles about the study in free
weekly community newspapers and targeted television
programming to patients waiting to see their doctor in
the waiting rooms of community general practices.
People interested in enrolling will be invited to contact
the study centre at the University of Auckland’s National
Institute for Health Innovation (NIHI) by free telephone
to obtain further information, complete informed con-
sent and undergo eligibility pre-screening. We hope to
recruit as many Māori (indigenous New Zealanders) as
possible to be able to test any effect of the intervention
on Māori compared with non-Māori participants, be-
cause 40% of Māori smoke tobacco and have a high bur-
den of smoking-related illness.
Randomisation, allocation concealment and sequence
generation
Callers will be told about the trial and asked if they
would like to take part by a research assistant. Ifinterested, they will be asked for basic demographic data
(age, sex and ethnicity) and checked to see if they meet
the trial inclusion criteria. Those who provide further
details about their level of nicotine dependence (deter-
mined by the Fagerström Test for Nicotine Dependence
[FTND] questionnaire [24]) will be randomised by a
central computer programme to one of the three study
groups using stratified block randomisation with block
sizes of nine. The randomisation sequence will be pre-
pared in advance by the study statistician (VP) but will
be concealed from research assistants enrolling partici-
pants. Participants will be assigned to the 16 mg e-
cigarette and nicotine patch groups in a ratio of 1:1 (290
in each) and to the nicotine e-cigarette and placebo e-
cigarette groups in a ratio of 4:1 (73 in the latter arm).
Three stratification factors will be used: ethnicity
(Māori, Pacific, non-Māori non-Pacific), sex (male/fe-
male) and level of nicotine dependence (> 5 or ≤ 5
on the FTND [24]).
Blinding
Due to the nature of the treatment it is not possible to
blind participants to the use of e-cigarettes or nicotine
patch. However, participants will be blind to the alloca-
tion of nicotine or placebo e-cigarettes as there is no dif-
ference in appearance or odour of the mist emitted from
the 16 mg/ml nicotine and 0 mg/ml nicotine cartridges,
nor do they differ in physical appearance. Members of
the trial steering committee, management committee,
and other team members (with the exception of the pro-
ject co-ordinator and research assistants) will remain
blind to treatment allocation until the code is broken
after the last follow-up call is completed and the data
recorded. The project co-ordinator and research assis-
tants are not blinded as they are responsible for distrib-
uting the treatment to participants. To minimise the risk
of bias, strict protocols for follow-up assessment proce-
dures will be developed and the research assistants
trained in adhering to these.
Study interventions
Participants will be randomly allocated to Elusion™ e-
cigarettes supplied by PGM International with nicotine car-
tridges (16 mg), to nicotine patch (HabitrolW 21 mg patch,
distributed in NZ by Novartis Consumer Health Australasia
Pty. Ltd.) or to e-cigarettes with placebo (0 mg) cartridges
in a ratio of 4:4:1. Participants issued with an e-cigarette
will be instructed to charge the batteries daily for reliable
operation using a USB charger that comes with the device,
alone or in combination (if needed) with an adaptor plug.
Participants in the 16 mg nicotine e-cigarette treat-
ment arm will be sent (by courier) a free e-cigarette and
sufficient nicotine cartridges (16 mg/ml) to last for four
to five weeks. Participants will be instructed to use the
Bullen et al. BMC Public Health 2013, 13:210 Page 4 of 8
http://www.biomedcentral.com/1471-2458/13/210device ad libitum one week before their quit day to
familiarise themselves with its operation and on their
designated quit day will stop smoking tobacco cigarettes
and instead use the e-cigarette exclusively for the next
12 weeks.
Those in the placebo e-cigarette arm will be sent a free
e-cigarette and cartridges containing 0 mg nicotine. Par-
ticipants will use the device in the same manner as de-
scribed above for the nicotine e-cigarette treatment
group. The cartridges will be labelled in such a way that
participants cannot detect if they contain nicotine.
In the nicotine patch arm, participants will be sent (by
post) vouchers to be exchanged for a minimal dispensing
fee (NZ$3) at any community pharmacy for 21 mg (full
strength, 24 hour) nicotine patches. All participants will
receive a $5 voucher to be used at any community phar-
macy on any product they wish, to cover their out of
pocket expenses. Participants will use the nicotine patch
daily for one week before their quit day to familiarise
themselves with its use. On their designated quit day
they will stop smoking and use nicotine patches daily for
the next 12 weeks. This dosing regimen is consistent
with what is now regarded as standard treatment in NZ
and many other countries. The 21 mg strength patch is
likely to be sufficient nicotine replacement for the ma-
jority of smokers recruited into the trial.
All participants will be referred to the NZ toll-free
smoking cessation support helpline, Quitline (www.quit.
org.nz), for a standardised cessation behavioural support
programme delivered by trained advisors, with a mini-
mum of one follow-up support telephone call over 8–
12 weeks. If people do not want to receive this support,
they will be able to access other Quitline supportNicotine e-cigs  
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Figure 1 Trial schema showing key design features and timelines.services such as ‘Txt2Quit’ (a mobile phone based sup-
port service), ‘QuitCoach’ (an internet based support ser-
vice), and the ‘Quitter’s community’ (an internet based
blogging forum) (Figure 1).
Baseline assessments
Following randomisation the following additional baseline
data will be collected from each participant: Demographic
information: socio-economic position (based on education
level attained); Smoking history: age when started smoking,
number of cigarettes smoked per day, number of years as
regular smoker, type of cigarettes smoked per day (e.g. roll-
your-own or factory-made), usual pouch/pack size (and
how long a pack lasts), number of previous unsuccessful at-
tempts to give up in past 12 months and the method used
including past history of any e-cigarette use; Other smoking
related information: self-rated chances of quitting, other
household members smoking at home or in cars with par-
ticipant; Use of any other smoking cessation treatments: use
of NRT or non-nicotine methods of cessation; Physical
signs and symptoms associated with withdrawal: measured
using the Autonomy Over Smoking Scale (AUTOS) [25];
Chances of quitting: self-rated chances of quitting success
measured on a scale of 1–5; Concomitant medication: infor-
mation about types of medication currently used; Behav-
ioural factors in smoking dependence: measured using the
Glover-Nilsson Smoking Behavioural Questionnaire (GH-
SBQ) [26]. A total GN-SBQ score is calculated by summing
all 11 items (range 0 to 4) with a score < 12 indicating a
mild level of behavioural dependence, 12–22 a moderate
level of behavioural dependence, 23–33 a strong level of be-
havioural dependence and >33 a very strong level of behav-
ioural dependence.3 months 6 months
e patch daily
Primary 
end-point
g/ml nicotine 
 ad libitum
mg/ml nicotine 
 ad libitum
Follow-up
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The primary outcome for the trial is the proportion
of participants who maintain sustained (continuous)
abstinence from smoking for six months after their quit
day. Abstinence is defined using the Russell Standard
(i.e. intention to treat analysis, smoking five cigarettes in
all [from the Quit date], plus biochemical verification of
self-reported abstinence via exhaled carbon monoxide
[CO] measurement, using the Bedfont Microplus device,
of less than 10 parts per million) [27].Secondary outcomes
The following secondary outcome measures are being
assessed in all participants at quit day and at one, three
and six months after the Quit date: Continuous abstin-
ence (as defined, at one and three months); Seven-day
point prevalence: defined as the proportion of partici-
pants who self-report having smoked no cigarettes (not
even a puff ) in the past 7 days; Use of cigarettes: smok-
ing at any time-point will trigger the following assess-
ments - number of cigarettes smoked per day;
proportion of participants who have significantly re-
duced daily smoking (defined as reducing consumption
by at least 25% in terms of numbers of cigarettes per day
or weight of loose tobacco per day); Participants’ treat-
ment compliance: number of patches or e-cigarette car-
tridges used per day; early stopping and reasons why;
Perception of the product: participant views on using e-
cigarettes or patches as a smoking cessation aid (includ-
ing what they liked and disliked about it and whether
they would recommend the treatment to another
smoker); Use of any other smoking cessation treatments;
Physical signs and symptoms associated with withdrawal;
Pre-quitting stage of addiction and smoking latency:
using a scale for latency to smoking developed by
Ursprung et al. [28]. Adverse events: Information regard-
ing any adverse events and whether they are related to
treatment.Sample size
A sample size of 657 people (292 in both nicotine-
cigarette and nicotine patch groups and 73 in the
placebo e-cigarette group) will provide 80% power at a
two-sided p = 0.05 to detect an absolute difference of
10% in smoking abstinence rates between the nicotine e-
cigarette and patch groups, and a difference of 15%
between the nicotine and placebo e-cigarette groups.
This assumes quit rates of 15% in the placebo e-cigarette
group and 20% in the nicotine patch group (based on
meta-analyses of NRT trials by Fiore et al. [29] and our
own trials of nicotine patch [30]). This sample size al-
lows for analysis of consistency of effects for pre-
specified subgroups (e.g. Maori, non-Maori) to beassessed. Based on our previous experience we estimate
recruitment will take approximately 12–15 months [31].
Withdrawal criteria
Should participants require discontinuation of study
treatment for any reason, (such as significant intolerance
to the study treatment, any serious clinical adverse
event, inter-current illness, pregnancy or other condition
that indicates to the principal investigator that continued
treatment is not in their best interest) or if they elect to
cease taking treatment, follow-up calls and data collec-
tion will continue as scheduled as if they were continu-
ing with the randomised treatment. If the participant
discontinues treatment due to a serious adverse event,
the participant will be followed until the event resolves
or there is a return to a clinically acceptable medical
status. Participant deaths or serious adverse events
within 30 days of discontinuation will be reported to the
project co-ordinator.
Data management
We will capture all study data on a web-based data man-
agement system using an Oracle database. Validation
rules for each case record form have been pre-specified
and include range checks so inaccuracies in data collec-
tion can be identified early. A query is raised for values
outside the allowed range or if data are missing, and the
form amended as soon as a query is resolved.
Data monitoring
An independent study monitor will perform audits of
every randomised participant’s record and ensure that
study documentation is up-to-date, record keeping
adheres to the study protocol and with regulatory re-
quirements, and handling of the study medication is
appropriate.
Statistical analysis
A senior biostatistician determined the sample size and
wrote the statistical analysis plan agreed upon by all
members of the Steering Committee specifying a priori
all analyses to be undertaken. All statistical analyses will
be performed using SAS version 9.3 (SAS Institute Inc.
Cary, North Carolina, US) and R version 2.11.1 software
(www.r-project.org). All regression analyses will be
conducted for the following two comparisons: 16 mg
e-cigarette versus nicotine patch groups; and 16 mg e-
cigarette versus 0 mg e-cigarette groups.
No interim analyses will be undertaken. All tests of
significance will be two-tailed. The primary analyses will
be carried out on an intention to treat (ITT) basis. The
ITT population will comprise all randomised partici-
pants regardless of whether they actually satisfied the
entry criteria, the treatment was actually received and
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The numbers discontinuing treatment prematurely for
any reason will be summarised by treatment group and
by reasons for discontinuation. The incidence of all
suspected serious adverse treatment reactions will be
summarised by treatment group in line with the CON-
SORT 2010 recommendations [32]. Simple incidence
rates, relative and absolute risks, numbers needed to
treat will be calculated for all binary variables, and the
treatment groups will be compared using chi-squared
tests with multiple logistic regression analysis adjusting
for other variables as appropriate. The distribution of all
continuous outcomes will be assessed for normality and
skewed data will be subjected to an appropriate transform-
ation before analysis. The change from baseline in physical
signs and symptoms associated with withdrawal (AUTOS)
[25] and number of cigarettes smoked per day will be
analysed using repeated measures models adjusting for
baseline value. The proportion of participants who have sig-
nificantly reduced their daily smoking level (defined as re-
ducing consumption by at least 50% in terms of numbers
of cigarettes per day) will be calculated, and in users of
loose tobacco, the size of pouch/package currently bought
and number of days taken to smoke its contents measured.
Finally, the number of other quit attempts in the last six
months will be calculated.
A per-protocol analysis will be performed for the pri-
mary analysis to check the robustness of the results
where participants with any major protocol violations
such as cross-over treatments, withdrawals and loss to
follow-up will be excluded. Secondary analyses will be
conducted with overall cessation rates corrected for dis-
cordance between reported and biochemically confirmed
cessation. The consistency of effects for pre-specified
sub-groups will also be assessed using tests for hetero-
geneity. Time-to-first-lapse will be analysed using
Kaplan-Meier curves, the log rank test and Cox propor-
tional hazards regression analysis.
Cost effectiveness analysis
If the primary outcome of the trial is positive then cost
analyses will be undertaken. Cost outcomes will include
cost per quitter, cost per person reducing their daily
cigarette consumption and incremental cost-effectiveness
ratio. These data will then be compared with data from the
NZ Quitline and other cessation service providers, in
addition to information from various international studies,
using a health sector perspective. The tobacco expenditure
savings to smokers who quit or cut down will also be calcu-
lated, especially to low-income smokers, using data on the
daily amount smoked prior to quitting and the price of the
products smoked. For those who cut down daily consump-
tion by 25% or more, the cost savings per person reducing
their daily cigarette consumption will be calculated.Ethical considerations
Ethics approval was granted from the New Zealand Minis-
try of Health’s Northern Ethics Committee (Ethics number
NTX/10/11/111). Verbal consent will be obtained at the
time of contact with the research team. However, a written
consent form and patient information sheet will be posted
to participants for their information, requesting that they
send it back to the study centre in a pre-paid envelope,
once signed. All data will be entered, stored and backed-up
in a secure manner via a password-protected data manage-
ment system. Participants will be acknowledged in all publi-
cations and presentation of the results.
Discussion
There are many challenges with the design of this study.
A key issue is that of intervention product selection.
There is a large and growing number and diversity of e-
cigarette products on the market, with only limited
evidence available on their performance and quality. E-
cigarettes differ in their characteristics such as the ability
to deliver vapour reliably, the concentration of nicotine
in the solution, flavour and other additives, and amount
of vapour produced [31]. These differences may impact
on the efficacy and acceptability of a particular brand or
model so it is possible that different trial findings may
be obtained using other brands or models of e-cigarette.
Furthermore, e-cigarettes are evolving rapidly and a
brand tested in a trial may no longer be on the market
by the time the study is completed and results
published.
We chose to use a particular brand (Elusion™) and
model of e-cigarette for three reasons: its wide availabil-
ity and popularity in New Zealand and Australia in
2011; we were able to obtain good evidence of the qual-
ity of cartridge solution production; and it was made
available to us at no cost by the distributor without
restrictions.
The choice of a ‘usual care’ comparator was not
straightforward. We elected to use the 21 mg nicotine
patch, by far the most widely used NRT product in New
Zealand. Patch use will also enable us to assess whether
any excess of adverse outcomes is due to the e-cigarette.
The alternative comparator most seriously considered
was the medicinal nicotine inhaler because of its similar
use characteristics to e-cigarettes (oral inhalation, on de-
mand use, use of hands to apply). However, it is not
subsidised in NZ and to include it would have added
substantial cost; also its use is aversive to start with and
so a barrier for many people [33]. We chose a three-arm
design with a placebo e-cigarette arm to answer the
question of whether any observed efficacy could be due
to behavioural replacement alone.
Users report needing time to familiarise themselves
with e-cigarettes to get satisfaction [21,32], and studies
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levels associated with e-cigarette use were undertaken in
experienced users [33]. We have attempted to address
this by providing participants with detailed illustrated in-
structions of how to use e-cigarettes, and requiring that
they try them for a week prior to embarking on their
quitting attempt.
The trial will report on clinical efficacy and adverse ef-
fects over a six month period of observation. This
follow-up period is sufficient to determine if smokers
are assisted to quit and to see if the use of nicotine e-
cigarettes leads to an excess of adverse effects after eight
week’s use over and above placebo e-cigarettes or nico-
tine patch. The results will make a valuable contribution
to the Cochrane Systematic Review on electronic ciga-
rettes for smoking cessation and reduction [34].
The study does not address the safety of long-term use
of e-cigarettes (beyond 13 weeks). Neither will the study
address the role of e-cigarettes as a ‘gateway’ product to
tobacco smoking or a trigger to relapse to tobacco
smoking. To answer these questions will require other
studies using different designs.
Finally, our study will not provide a definitive answer
to address all e-cigarette regulation issues. However,
should the findings be in favour of nicotine e-cigarettes
without additional adverse effects then it will establish a
new balance between clinical benefit and harm for three
month’s use of e-cigarettes.Abbreviations
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